Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens

Figure 6 During follow-up after the cessation of peginterferon alpha treatment. A: The hepatitis B surface antigen recurrence rate in the hepatitis B surface antibody (HBsAb) < 35.3 mIU/mL and HBsAb ≥ 35.3 mIU/mL groups at the cessation of peginterferon alpha (peg-IFN-α) treatment. ^bP < 0.01; B: The dynamics of median alanine aminotransferase and aspartate transaminase levels during follow-up after the cessation of peg-IFN-α treatment. HBsAb: Hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; AST: Aspartate transaminase.